Therefore, many PARP inhibitors have been developed and FDA-approved as anti-tumour molecules for various cancers, such as ovarian cancer, with either somatic or germline BRCA1/2 mutations [22], [23]. This evidence concerns the gene BRCA1 and ovarian carcinoma.